![Richard Marsden](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard Marsden
Director/Board Member at
Synairgen Research Ltd.
Net worth: 10 $ as of 2025-12-30
Profile
Richard James Marsden currently works at Synairgen Research Ltd., as Director from 2004.
Mr. Marsden also formerly worked at Synairgen Plc, as Chief Executive Officer & Executive Director from 2009 to 2025, MedImmune Ltd., as Respiratory Director, Southampton Asset Management Ltd., as Managing Director from 2005 to 2014, and Respironics Ltd., as Manager-Cystic Fibrosis Business Development.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SYNAIRGEN PLC 0.09% | 2024-12-30 | 995,771 ( 0.09% ) | 10 $ | 2025-12-30 |
Richard Marsden active positions
| Companies | Position | Start |
|---|---|---|
Synairgen Research Ltd.
 Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in respiratory biology and develops novel therapies | Director/Board Member | 2004-06-06 |
Former positions of Richard Marsden
| Companies | Position | End |
|---|---|---|
| SYNAIRGEN PLC | Chief Executive Officer | 2025-06-30 |
Southampton Asset Management Ltd.
 Southampton Asset Management Ltd. Investment ManagersFinance SAM works closely with the University to enhance development of their intellectual property. Through external partners, they develop spin-out firms, joint ventures and industry-led deals. They draw on the University's areas of expertise and have invested in ventures in oil and gas exploration, pharmaceuticals, nanotechnology and optoelectronics. Actual spin-out firms have been active in areas such as electromagnetic sensing services designed to detect the presence of offshore oil and gas, large-scale project management software, new methods for the synthesis of peptides and proteins, drug evaluation, testing and discovery in CNS disorders, photonic crystal technology, insect pest control solutions, optical solutions via laser wavelength conversion and integrated optical circuit technology, specialty optical fiber, cancer and heart disease drug treatment through histone deacetylase (HDAC) inhibitors, and gamma-ray detector systems. | Director/Board Member | 2014-03-16 |
Respironics Ltd.
 Respironics Ltd. Financial ConglomeratesFinance Develops and manufactures medical and healthcare products | Corporate Officer/Principal | 2002-12-31 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
16
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Health Technology |
Synairgen Plc
 Synairgen Plc Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for respiratory disorders | Health Technology |
Respironics Ltd.
Respironics Ltd. Financial ConglomeratesFinance Develops and manufactures medical and healthcare products | Finance |
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance SAM works closely with the University to enhance development of their intellectual property. Through external partners, they develop spin-out firms, joint ventures and industry-led deals. They draw on the University's areas of expertise and have invested in ventures in oil and gas exploration, pharmaceuticals, nanotechnology and optoelectronics. Actual spin-out firms have been active in areas such as electromagnetic sensing services designed to detect the presence of offshore oil and gas, large-scale project management software, new methods for the synthesis of peptides and proteins, drug evaluation, testing and discovery in CNS disorders, photonic crystal technology, insect pest control solutions, optical solutions via laser wavelength conversion and integrated optical circuit technology, specialty optical fiber, cancer and heart disease drug treatment through histone deacetylase (HDAC) inhibitors, and gamma-ray detector systems. | Finance |
Synairgen Research Ltd.
Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in respiratory biology and develops novel therapies | Commercial Services |
- Stock Market
- Insiders
- Richard Marsden
